Arcturus Therapeutics Holdings Inc.
About Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $82.0M
- Net income
- -$65.8M
- Total assets
- $271.1M
- Market cap
- $207.5M
- Operating margin
- -93.0%
- Net margin
- -80.2%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $82.0M
- Operating expenses
- $158.3M
- Operating income
- -$76.3M
- Net income
- -$65.8M
- EPS (basic)
- $-2.40
- EPS (diluted)
- $-2.40
Balance sheet
- Total assets
- $271.1M
- Current assets
- $241.4M
- Total liabilities
- $57.2M
- Current liabilities
- $36.4M
- Shareholders’ equity
- $214.0M
Cash flow
- Operating cash flow
- -$74.3M
- Investing cash flow
- -$230.0K
- Financing cash flow
- $13.4M
- Net cash flow
- -$61.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $207.5M
- EPS (diluted)
- $-2.4
- Shares outstanding
- 29.1M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 22, 2013
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $65.8M in FY2025.
- Revenue grew 564% from FY2021 to FY2025.
- Trading 69% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Arcturus Therapeutics Holdings Inc..
Write a review
News about Arcturus Therapeutics Holdings Inc.
News & sentiment via Polygon.io
